Dr. Lane’s research focuses on the biology of high-risk hematologic malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN), to identify novel therapeutic targets and to understand treatment resistance. He has also identified new cancer genes including tumor suppressors that escape X inactivation (EXITS genes) as mediators of sex bias in tumor genomes.
He is an associate professor of medicine at Harvard Medical School, Co-Leader of the Dana-Farber/Harvard Cancer Center Leukemia Program, and a laboratory investigator in the Division of Hematologic Neoplasia in the Department of Medical Oncology at Dana-Farber. He is director of the BPDCN Center at Dana-Farber. He is also an associate member of the Broad Institute of Harvard and MIT.
Dr. Lane received a bachelor’s degree in biomedical engineering from Vanderbilt University, and an MD and PhD from Washington University. He completed a residency in internal medicine at Brigham and Women’s Hospital and fellowships in hematology and medical oncology at the Dana-Farber Cancer Institute.